Status:
COMPLETED
Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx
Lead Sponsor:
Stanford University
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To test the ability of new imaging techniques to monitor and predict response of pancreatic cancer to radiation and/or chemotherapy.
Eligibility Criteria
Inclusion
- Adult patients (\>18) with histologically confirmed adenocarcinomas of the pancreas with a - treatment plan consisting of definitive or palliative radiation therapy and/or chemotherapy with or without surgery.
- Negative urine pregnancy test if a woman of child-bearing potential (WOCBP).
- WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study period.
- All patients will be evaluated in a uniform manner at the Stanford GI Combined Modality Tumor Board to determine eligibility.
Exclusion
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- 2\. Any concurrent malignancy other than non-melanomaskin cancer, or carcinomainsitu of the cervix. Patients with a previous malignancy without evidence of disease for \>5 years will be allowed to enter the trial.
- 3\. WOCBP who is pregnant or breastfeeding. 4. Inability to sign written consent.
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00767273
Start Date
October 1 2006
End Date
December 1 2007
Last Update
June 11 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305